Apr 25, 2014 by Peter StephensThis Is Dividend Stock Johnson & Johnson’s Major WeaknessAlthough diversification can sometimes be a strength, it can also prove to be a double-edged sword in the long run. Here’s how.
Apr 17, 2014 by Peter StephensJohnson & Johnson's 3 Major StrengthsWhat are the three key reasons why J&J could be a top performer in the future?
Apr 7, 2014 by Peter StephensCan J&J's Pharma Segment Deliver Meaningful Growth?In the final part of a three-part series, I take a deep dive into J&J's pharmaceuticals segment and ask whether it's as attractive as many investors believe.
Mar 28, 2014 by Peter StephensDon't Underestimate J&J's Best-Known ProductsIn the second of a three-part series I take a closer look at J&J's (NYSE: JNJ) consumer segment to find out if it could make the stock take off.
Mar 25, 2014 by Peter StephensIs J&J's Forgotten Half About to Take Off?In the first of a three-part series, I put Johnson & Johnson's medical devices and diagnostics segment under the investment microscope.
Mar 20, 2014 by Peter StephensWhy Philip Morris Could Be a Winning StockPhilip Morris could be a strong performer in future. Here's why.
Mar 20, 2014 by Peter StephensIs Novartis' Strategy a Winning One?Novartis has changed to a new strategy. Is it likely to be a successful one?
Mar 19, 2014 by Peter StephensIs Procter & Gamble a Buy at Current Levels?With shares disappointing in recent years, is Procter & Gamble now attractive?
Mar 19, 2014 by Peter StephensBetter Buy: GlaxoSmithKline, AbbVie, or Merck?Shares in GlaxoSmithKline have underperformed the index in recent years. Does this mean the stock is undervalued?
Mar 18, 2014 by Peter StephensDoes Bristol-Myers Squibb Offer Good Value?Having had a strong performance in recent years, does Bristol-Myers Squibb still offer good value for your money at current price levels?
Mar 17, 2014 by Peter StephensCan Pfizer Outperform in 2014?After tracking the index for five years, Pfizer could be worth buying. Here's why.
Mar 14, 2014 by Peter StephensCan AbbVie Continue Its Bull Run?After an impressive share price performance since it listed, is AbbVie still worth buying?
Mar 14, 2014 by Peter StephensBetter Buy: Johnson & Johnson, Pfizer, or Bristol-Myers Squibb?Is the relative stability provided by Johnson & Johnson's diversified business model a major advantage when compared to Pfizer and Bristol-Myers Squibb?
Mar 13, 2014 by Peter StephensCan Eli Lilly Continue its Bull Run?Despite some disappointing news, Eli Lilly's stock has made a strong start to 2014. Can it keep going?
Mar 12, 2014 by Peter StephensBristol-Myers Squibb: More Than Just a Relief Rally?Shares in Bristol-Myers Squibb performed relatively positively last week. Can they keep it going?
Mar 11, 2014 by Peter StephensIs Merck a Buy at Current Price Levels?After a strong recent run, are shares in Merck (NYSE: MRK) still worth buying?
Mar 10, 2014 by Peter StephensCan Merck Keep Its Bull Run Going?Shares in Merck have made a strong start to 2014. Can they keep going?
Mar 9, 2014 by Peter StephensHas Celgene Corporation Run Out of Steam in 2014?After an awesome 2013, Celgene (NASDAQ: CELG) has made a bad start to the year. Can it recover?
Mar 7, 2014 by Peter StephensCan Bristol-Myers Squibb Keep Its Bull Run Going in 2014?The year 2013 was a great one for Bristol-Myers Squibb (NYSE: BMY); 2014 could also be a strong year due to a potential catalyst.
Mar 6, 2014 by Peter StephensCan Roche Keep Its Bull Run Going?Despite mixed recent news flow, Roche remains a company with significant potential.
